The AustralaSian COVID-19 Trial (ASCOT) has pinpointed the most efficient level of anti-clotting treatment needed for patients hospitalised with COVID-19. Patients in hospital with COVID-19 are at increased risk of blood clots (or thromboses), which in turn may contribute to the development of organ failure. Almost all these patients will receive some degree of anti-clotting medication.
In an international study, the ASCOT team, including Prof Bala Venkatesh and Prof Vivek Jha from The George Institute, conducted a randomised clinical trial to test the different levels of anti-clotting medication in more than 1,500 patients in Australia, New Zealand, India and Nepal.
For details, refer to the media release on this page.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
